Yantai Dongcheng Biochemicals (002675.SZ) Completes Phase III Clinical Trial for Fluorine [18F]Sirateptide Injection

Stock News11-28

Yantai Dongcheng Biochemicals Co., Ltd. (002675.SZ) announced that its subsidiary, Yantai Lannacheng Biotechnology Co., Ltd. ("Lannacheng"), has completed Phase III clinical trials for Fluorine [18F]Sirateptide Injection. This PSMA-targeted radiopharmaceutical diagnostic agent is designed for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in prostate cancer patients, including those undergoing initial radical treatment with suspected metastases or experiencing biochemical recurrence with elevated prostate-specific antigen (PSA) levels.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1126384229?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-28 17:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126384229","market":"sh","top_or_hot":-1,"title":"Yantai Dongcheng Biochemicals (002675.SZ) Completes Phase III Clinical Trial for Fluorine [18F]Sirateptide Injection","media":"Stock News","content":"<p>Yantai Dongcheng Biochemicals Co., Ltd. (002675.SZ) announced that its subsidiary, Yantai Lannacheng Biotechnology Co., Ltd. (\"Lannacheng\"), has completed Phase III clinical trials for Fluorine [18F]Sirateptide Injection. This PSMA-targeted radiopharmaceutical diagnostic agent is designed for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in prostate cancer patients, including those undergoing initial radical treatment with suspected metastases or experiencing biochemical recurrence with elevated prostate-specific antigen (PSA) levels.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Yantai Dongcheng Biochemicals (002675.SZ) Completes Phase III Clinical Trial for Fluorine [18F]Sirateptide Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYantai Dongcheng Biochemicals (002675.SZ) Completes Phase III Clinical Trial for Fluorine [18F]Sirateptide Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-28 17:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Yantai Dongcheng Biochemicals Co., Ltd. (002675.SZ) announced that its subsidiary, Yantai Lannacheng Biotechnology Co., Ltd. (\"Lannacheng\"), has completed Phase III clinical trials for Fluorine [18F]Sirateptide Injection. This PSMA-targeted radiopharmaceutical diagnostic agent is designed for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in prostate cancer patients, including those undergoing initial radical treatment with suspected metastases or experiencing biochemical recurrence with elevated prostate-specific antigen (PSA) levels.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"002675","symbol_name":"东诚药业","start_time":0,"source_url":"","article_id":"1126384229","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126384229","pubTimestamp":1764322312,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Yantai Dongcheng Biochemicals Co., Ltd. (002675.SZ) announced that its subsidiary, Yantai Lannacheng Biotechnology Co., Ltd. (\"Lannacheng\"), has completed Phase III clinical trials for Fluorine...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"002675":"东诚药业","BK0239":"医药制造","III":"信息服务","BK4134":"信息科技咨询与其它服务"},"translate_title":"烟台东诚生化（002675.SZ）氟[18F]西拉肽注射液完成III期临床试验","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002675":1,"III":1},"content_text":"Yantai Dongcheng Biochemicals Co., Ltd. (002675.SZ) announced that its subsidiary, Yantai Lannacheng Biotechnology Co., Ltd. (\"Lannacheng\"), has completed Phase III clinical trials for Fluorine [18F]Sirateptide Injection. This PSMA-targeted radiopharmaceutical diagnostic agent is designed for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in prostate cancer patients, including those undergoing initial radical treatment with suspected metastases or experiencing biochemical recurrence with elevated prostate-specific antigen (PSA) levels.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1126384229","isCrawlerRequest":true}